

## Review

### Cite

Torres-Quesada O, Strich S, Stefan E (2022) Kinase perturbations redirect mitochondrial function. MitoFit Preprints 2022.11.  
<https://doi.org/10.26124/mitofit:2022-0011>

### Author contributions

All the authors have agreed the final version of this review.

### Conflicts of interest

The authors declare that they have no conflict of interest.

**Received** 2022-04-01

**Accepted** 2022-04-04

**Online** 2022-04-11

### Keywords

kinases, signaling, mitochondria, kinase inhibitors, cancer, drug off-target effects

# Kinase perturbations redirect mitochondrial function

 Omar Torres-Quesada<sup>1,2\*</sup>, Sophie Strich<sup>1</sup>,  
 Eduard Stefan<sup>1,2\*</sup>

1 Tyrolean Cancer Research Institute, Innrain 66, 6020 Innsbruck, Austria

2 Institute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria

\* Corresponding authors: [omar.torres@tkfi.at](mailto:omar.torres@tkfi.at) ; Tel 0043 512 570 48517 / [eduard.stefan@uibk.ac.at](mailto:eduard.stefan@uibk.ac.at) ; Tel 0043 512 507 57531

## Abstract

**Protein kinases take the center stage in numerous signaling pathways by phosphorylating compartmentalized protein substrates for controlling cell proliferation, cell cycle and metabolism. Kinase dysfunctions have been linked to numerous human diseases such as cancer. This has led to the development of kinase inhibitors which aim to target oncogenic kinase activities. The specificity of the cancer blockers depends on the range of targeted kinases. Therefore, the question arises of how cell-type-specific off-target effects impair the specificities of cancer drugs. Blockade of kinase activities has been shown to converge on the energetic organelle, the mitochondria. In this review, we highlight examples of selected major kinases which impact mitochondrial signaling. Further, we discuss pharmacological strategies to target kinase activities which are linked to cancer progression and redirecting mitochondrial function. Finally, we propose that cell-based recordings of mitochondrial bioenergetic states might predict off-target or identify specific on-target effects of kinase inhibitors.**

## 1. Introduction

Cells transmit environmental cues through intracellular signaling networks to translate the spatiotemporal input signal into the appropriate cellular response. In numerous signaling pathways post-translational modifications (PTMs) and the formation of diverse molecular interactions (i.e. protein:protein, RNA/DNA:protein and small

molecule:protein interactions) take the center stage for adapting cellular functions through alterations of gene expression, cell proliferation and cell energy metabolism (Langeberg, Scott 2015; Nooren, Thornton 2003). Protein kinases are at the heart of numerous signaling pathways. Conventionally, kinases catalyze the transfer of the gamma phosphate of ATP to defined amino acids of their target proteins resulting in a change in enzymatic activity, cellular localization, stability and/or physical interactions. Most human phosphotransferases are serine/threonine kinases through phosphorylating hydroxyl groups of serines and threonines. The others are classified as tyrosine phosphorylating kinases (Ramms et al 2021; Taylor et al 2012b; Ubersax 2007).

Kinase deregulation has been linked to several human diseases, primarily carcinogenesis (Cohen 2002; Ramms et al 2021). Thus, kinases have become the subject of intensive academic and pharmaceutical research. Small molecules targeting decontrolled kinase activities currently are among the most effective drugs in target-oriented cancer therapy (Bhullar et al 2018; Karaman et al 2008; Zhang et al 2009). Kinase inhibitors (KIs) have received FDA approval for the treatment of a collection of malignancies (Roskoski 2019). Much more than 150 kinase-targeted drugs are in the late clinical phase trials and numerous are in the preclinical stage of drug development. Many of those molecules represent ATP-competitive inhibitors, especially for their use in cancer treatments (Bhullar et al 2018; Hartmann et al 2009).

In this review, we highlight a selection of major kinases which regulate mitochondrial function. Further, we discuss current pharmacological strategies which are based on small molecules/kinase inhibitors to target kinase activities linked to cancer progression showing diverse effects on mitochondria (Figure 1). First, we list a selection of major kinases that participate in modulating mitochondrial dynamics and bioenergetic states. Second, we present KI strategies that somehow redirect mitochondria signaling. Third, we emphasize off-target effects of anti-cancer small molecules and how drug-induced effects on mitochondria function may contribute to unintended pharmaceutical responses.

## 2. Protein kinases modulate mitochondria

Mitochondria are the powerhouses of the cell. Besides its central bioenergetic function, mitochondria adopt important roles in cellular signaling and they are central contributions to cell apoptosis, autophagy and cell differentiation (Gnaiger 2020; Rinaldi et al 2018). Phosphorylation of mitochondrial proteins has been connected with mitochondrial dysfunction. Besides aging diseases such as neurodegeneration, diabetes and cancer have been linked to deregulation of the central ATP producing organelle (Burté et al 2014; Wallace 2012). The current literature has identified at least 30 kinases which have been reported to be functionally linked and/or to phosphorylate mitochondrial proteins (Kotrasova et al 2021; Lucero et al 2019). Thus, we have decided to present a short selection of protein kinases linked to mitochondria which are targets of kinase blockers.

In the following, we discuss two membrane receptor pathways which are linked to kinase functions, G-protein coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs) respectively. Many extracellular stimuli are sensed by GPCRs to mobilize second messenger oscillations (Dorsam, Gutkind 2007). The cAMP-dependent protein kinase A (PKA) is one of the best-studied examples of a second messenger sensor (cAMP) and


allosteric protein complex (Ramms et al 2021; Taylor et al 2012a). Besides its multifaceted functions, macromolecular PKA complexes have been linked to mitochondrial physiology (Rinaldi et al 2018; Torres-Quesada et al 2017). Distinct PKA regulatory subunits are anchored to the mitochondrial outer membrane (mtOM) through the A kinase anchoring protein 1 (AKAP1) (Affaitati et al 2003). PKA substrates compartmentalized at the mtOM are the dynamin-related protein 1 (DRP1) and the voltage-dependent anion channel (VDAC). PKA phosphorylates DRP1 and thus blocks its translocation to the mitochondrial surface to influence mitochondrial fission (Chang, Blackstone 2007). PKA phosphorylates VDAC to modulate the  $\text{Ca}^{2+}$  uptake and control mitochondrial function such as energy production and the initiation of cell death (Bera, Ghosh 2001). In the mitochondrial matrix, PKA has been shown to phosphorylate the NADH:ubiquinone oxidoreductase (Complex I, CI) and the cytochrome *c* oxidase (Complex IV, CIV, COX). Phosphorylation of the CI (NDUFS4 subunit) has been demonstrated to increase the enzymatic activity and is relevant for its translocation from the cytosol into the mitochondria (De Rasmio et al 2008). In contrast, elevated levels of PKA cause the hyperphosphorylation of several COX subunits (i.e. COX1, COX4-1 and COX5b) which are associated with decreased CIV activity (Prabu et al 2006).

RTKs represent the second major receptor pathway, thus we would like to briefly review this cascade in the context of mitochondrial signaling. Growth factors fine-tune mitochondrial activity by redirecting intracellular kinase signaling. RTKs represent a family of precisely controlled receptors that control cell proliferation, cell differentiation, and cell death (Casaletto, McClatchey 2012; Lemmon, Schlessinger 2010). It has been shown that the mitogen-activated protein kinase pathway (MAPK) targets mitochondria displaying relevance for energy metabolism (Javadov et al 2014). The gatekeeper kinase MEK activates ERK1/2 by phosphorylation. In this context ERK1/2 activities have been linked to redirect mitochondrial (dys)function, mitophagy, and apoptosis. This may involve the phosphorylation of mitochondrial proteins such as DRP1 and TRAP1, thereby regulating the mitochondrial membrane potential ( $\Delta\Psi_{\text{mt}}$ ) and protecting cancer cells from apoptosis (Kotrasova et al 2021). Another highly conserved transduction cascade activated by growth factors is the phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT) pathway. AKT has been shown to compartmentalize with mitochondria and thus may phosphorylate elements of the electron transfer pathway (ET-pathway) at the level of the ATP synthase. This molecular event enhances the ATP production in cardiac cells (Yang et al 2013) and plays a role in the inactivation of several pro-apoptotic proteins at the mitochondria for inducing cell survival (Datta et al 1997). Activation of the PI3K pathway is linked to mitochondrial function via protein kinase C (PKC). Activated PKC shows colocalization with mitochondria and translocation into the mitochondrial matrix to phosphorylate target proteins. PKC activities are involved in preventing mitochondrial injury upon cellular stress (Lim et al 2016). The proto-oncogene tyrosine-protein kinases (SRC) are key regulators of cell proliferation, differentiation, survival, cell morphology and motility (Parsons, Parsons 2004). SRC kinases are cytoplasmic proteins. There are evidences of SRC localization to the mitochondria to act as molecular switch for controlling mitochondrial function (Djeungoue-Petga et al 2019). SRC kinases phosphorylate components of the ET-pathway such as CI subunits (i.e. NDUFV2 and NDUFB10) which increases the levels of respiration. SRC activates the succinate dehydrogenase (Complex II, CII) in response to cellular adaptation to nutrient availability (Acin-Perez et al 2014). Another kinase that contributes to adaptations of mitochondrial function and are activated by growth factors is the c-Jun N-terminal kinases (JNK). JNK

may have pro-apoptotic but also anti-apoptotic functions at the mitochondria, depending on the cell type and stimulus. For example, JNK is indirectly activated by cytochrome *c* release from mitochondria and it was shown to amplify the ROS generation at CI, contributing to cell death (Shen, Liu 2006; Zheng et al 2017). However, it has been shown that JNK is necessary for interleukin 3 (IL-3)-mediated cell survival via phosphorylation and inactivation of Bcl2-associated agonist of cell death (BAD) (Yu et al 2004).

Mitochondrial signaling is connected with metabolic control units and energy metabolism. One of the key sensors of energy homeostasis is the AMP-activated protein kinase (AMPK). AMPK activity increases in dependence of AMP and ADP levels. These are central and direct metabolic cues for adjusting the states of mitochondrial bioenergetics (Herzig, Shaw 2018). In the cytoplasm, AMPK is regulated by an activated trimeric LKB1/STRAD/MO25 complex. As a consequence of high-energy demand AMPK is found at the mtOM for phosphorylating several factors related to mitochondrial fission (i.e. DRP1, MFF), mitophagy and mitochondrial biogenesis (Zhang, Lin 2016). AMPK is a key player in maintaining mitochondrial quality control. In cellular energy stress conditions, mitochondrial populations present different morphologies and dynamics (i.e. changes in  $\Delta\Psi_{mt}$ , fragmentation or inhibitors of the ET-pathway) which activate AMPK feedback loops to further promote mitochondrial fission and autophagy, thus serving as a molecular rheostat of mitochondrial quality (Drake et al 2021; Zhang et al 2018). Another key kinase controlling mitochondrial quality is the PTEN-induced kinase 1 (PINK1). PINK1 mutations are linked to autosomal recessive familial Parkinson's Disease (PD) (Jones 2010). PINK1 is expressed in mammalian cells and it accumulates in specific mitochondria compartments, being found on the inner and outer mitochondrial membrane. PINK1 regulates Parkin, which acts as an E3 ubiquitin ligase. PINK1 recruits Parkin to depolarize mitochondria. While PINK1 is imported and rapidly degraded by mitochondrial proteases with intact membrane potential, PINK1 breakdown is impaired in mitochondria with reduced membrane potential thus serving as a quality control unit for ensuring mitochondrial quality (Wang et al 2020). In addition, PINK1 phosphorylates DRP1. Low levels of PINK1-phosphorylated DRP1 have been found in cells originating from PD patients. This may represent a novel mechanism of regulation of mitochondrial dynamics independently of Parkin (Han et al 2020). Moreover, loss of PINK1 has been linked with CI damage and oxidative stress (Morais et al 2014).

Here, we have listed a selection of major kinases linked to mitochondrial function. It pinpoints the high complexity of mitochondrial-centered kinase signaling pathways which converge at the energetic organelle at different levels. Many aspects of kinase:mitochondria interlinkage have not been unveiled yet due to enigmatic effects of non-specific kinase inhibitors on mitochondria.



**Figure 1. Perturbing the mitochondrial kinase network.** Mitochondria consist of four compartments: outer membrane (mtOM), intermembrane space (mtIMS), inner membrane (mtIM) and matrix. The oxidative phosphorylation (OXPHOS) system comprises the respiratory electron-transfer-pathway capacity (ET) and the ATP synthase where the reduced fuel substrates coming from the tricarboxylic acid cycle (TCA) and other metabolic pathways are oxidized by electron transfer, chemiosmotic coupling to the phosphorylation of ADP to ATP and intrinsically uncoupling by proton leak, cation cycling and electron leak (LEAK, *L*). Electrons fuel from NADH-linked substrates to CI and from succinate&rotenone to CII converging at the Q-junction and transferred to Complex III (CIII), cytochrome *c* (*c*) and CIV, where reduce a molecule of O<sub>2</sub> to produce H<sub>2</sub>O. The protonmotive force generated is dissipated at the ATP synthase to generate ATP from ADP. Growth factors bind to receptor-tyrosine kinases (RTKs) and may activate cell type specifically ERK, SRC, AKT and PKA kinases. These might be involved in directly/indirectly influencing activities of the respiratory complexes or mtOM proteins by phosphorylation and control mitochondrial dynamics and bioenergetics. AMPK, PKA and JNK are activated by diverse types of membrane

receptors (i.e. GPCRs and interleukin receptors, IL-R, respectively) and control mitochondrial fission, ET-pathway and apoptosis. AMPK and PINK1 are the mitochondrial rheostat for energy state and quality control in response to cellular stress. Kinase inhibitors (black boxes) modulate mitochondrial function by inhibiting kinase activities. The specificity and efficacy depend on cell type, timing and doses of the applied inhibitors which determine the portfolio of kinases (on-target and off-target) that are affected.

### 3. Kinase inhibitors affect mitochondrial function

Many anti-cancer therapies are designed to directly target specific molecules to antagonize cancer cell proliferation. Especially KIs targeting mutated kinases have proven the concept of personalized medicine with better outcomes for cancer patients. The specificities of these KIs have been extensively studied as a strategy for drug repurposing and understanding drug resistance mechanisms. Interestingly, it has been revealed that many KIs have unexpected activities on other cellular pathways thus explaining off-target effects (Klaeger et al 2017; Lin et al 2019; ZhangLoughran 2011).

Specific-spectrum KIs represent one strategy to tackle aberrant cell functions by targeting a single kinase. However, off-target effects of KI affect other cellular functions amongst others e.g. the mitochondrial bioenergetic states (Wynn et al 2011). For example, BRAF inhibitors (i.e. vemurafenib, dabrafenib) have been designed to block the BRAF kinase mutation V600E in melanoma (Karoulia et al 2017; Mayrhofer et al 2020; Röck et al 2019). In contrast, MEK inhibitors target wild-type proteins (Caunt et al 2015). They are combined with BRAFi to reduce emerging resistance mechanisms in the melanoma patients (Dossett et al 2015; Fleischmann et al 2021). Despite the high specificity of mutated BRAF, BRAFi influence mitochondrial function. In melanoma cells, BRAFi treatment drives the intrinsic aerobic glycolytic phenotype inherent in cancer cells to a more oxidative metabolism by increasing mitochondrial OXPHOS and elevating ROS production (Avagliano et al 2020). Other specific KIs targeting the PI3K pathway have been identified to redirect mitochondrial function. For example, AKT inhibitors are proposed to be a new generation of more efficient blockers of cancer (i.e. capivasertib and ipatasertib, Phase III clinical trials). They are supposed to target the protective effect of AKT on mitochondria (Martorana et al 2021). However, it is still elusive how the mitochondrial bioenergetic states are altered. In the case of the PKC inhibitor cisplatin, it has been shown that cancer cells treated with this KI undergo apoptotic cell death which is related to enhancing of ROS levels, mtDNA damage and reduced energy production (Choi et al 2015). Kinase blockade of other mitochondria-associated kinases such as JNK and SRC could be beneficial for cancer therapy but the exact impact on mitochondrial respiration has not been evaluated yet.

Besides the discussed KIs, the largest group of kinase blockers used for cancer therapy are the tyrosine-kinase inhibitors (TKIs). They have been established in recent years to become the preferential first- and second-line therapy for many cancer types. TKIs inhibit the binding of ATP to the catalytic binding site of tyrosine kinases. It is of note, that they differ in the spectrum of targeted kinases, the pharmacokinetics and side effects (Hartmann et al 2009; Rodriguez-Hernandez et al 2020). For example, sorafenib and sunitinib target growth factor receptors (i.e. VEGFR, PDGFR). Sorafenib targets around 70 kinases and sunitinib blocks 170 (Karaman et al 2008). TKIs have been reported to cause

mitochondrial damage. Effects on the ET-pathway (i.e. CI damage), apoptosis, mitophagy, ROS production, and altered mitochondrial dynamics (mitochondrial fission and fragmentation) are well-described effects related with the mito-toxicity of TKIs (i.e. cardiotoxicity or hepatotoxicity) (Rodriguez-Hernandez et al 2020; Vuda, Kamath 2016). These effects are related to off-target drug effects, therefore, the knowledge of kinase inhibition related to physiological and pathological functions which are connected to mitochondria perturbations is necessary to anticipate specificities and drug efficacies.

Other small molecule-related intervention strategies have been reported to produce side effects and to affect mitochondrial function. For example, metformin is extensively used as therapy for type-2 diabetes patients. Metformin in a pharmacological dose improves mitochondrial respiration by promoting AMPK-dependent mitochondrial fission. In lower doses, metformin has been identified to target CI and, inhibit PKA-dependent CIV activation and the mitochondrial glycerophosphate dehydrogenase (LaMoia et al 2022; Wang et al 2019). Moreover, metformin also indirectly activates AMPK by activation of LKB1 (Foretz et al 2010) thus influencing cellular energy metabolism. This may involve mitochondria but the precise mechanistic mode of regulating mitochondrial bioenergetics remains poorly understood. Other examples of small molecules modulating mitochondrial dynamics (i.e. biogenesis) have been described. This involves, for example the GPCR-agonist formoterol which activates the beta-2 adrenergic receptor pathway, which somehow redirects mitochondrial bioenergetics (Cameron et al 2017).

In conclusion, kinase inhibitors are the drug of choice for treating different types of cancers. Their varying target specificities contribute to a more or less effective blockade of oncogenic signaling events. Off-target effects of small molecules are the major drawbacks of effective therapies. Amongst others, these are related to unwanted effects on mitochondria function which are interlinked with kinase activities and thus are hampered upon small molecule exposure. Therefore, we would like to propose that more systematic profiling of mitochondrial bioenergetic states in the presence and absence of lead molecules or kinase drugs could become an asset for anticipating non-desired off-target drug features.

## Acknowledgements

We thank Gabi Reiter and Erika Lentner for managing support and Philipp Tschaikner for comments on the manuscript. This work was supported by grants from the Austrian FFG-Bridge program MitoKin (877163) and the Austrian Science Fund (FWF; P27606, P30441, P32960, P35159).

## References

- Acín-Pérez R, Carrascoso I, Baixauli F, Roche-Molina M, Latorre-Pellicer A, Fernández-Silva P, Mittelbrunn M, Sanchez-Madrid F, Pérez-Martos A, Lowell CA, Manfredi G, Enríquez JA (2014) ROS-triggered phosphorylation of complex II by Fgr kinase regulates cellular adaptation to fuel use. *Cell Metab* 19:1020-33. <https://doi.org/10.1016/j.cmet.2014.04.015>
- Affaitati A, Cardone L, de Cristofaro T, Carlucci A, Ginsberg MD, Varrone S, Gottesman ME, Avvedimento EV, Feliciello A (2003) Essential role of A-kinase anchor protein 121 for cAMP signaling to mitochondria. *J Biol Chem* 278:4286-94. <https://doi.org/10.1074/jbc.M209941200>

- Avagliano A, Fiume G, Pelagalli A, Sanita G, Ruocco MR, Montagnani S, Arcucci A (2020) Metabolic plasticity of melanoma cells and their crosstalk with tumor microenvironment. *Front Oncol* 10:722. <https://doi.org/10.3389/fonc.2020.00722>
- Bera AK, Ghosh S (2001) Dual mode of gating of voltage-dependent anion channel as revealed by phosphorylation. *J Struct Biol* 135:67-72. <https://doi.org/10.1006/jsbi.2001.4399>
- Bhullar KS, Lagaron NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV (2018) Kinase-targeted cancer therapies: progress, challenges and future directions. *Mol Cancer* 17:48. <https://doi.org/10.1186/s12943-018-0804-2>
- Burté F, Carelli V, Chinnery PF, Yu-Wai-Man P (2014) Disturbed mitochondrial dynamics and neurodegenerative disorders. *Nat Rev Neurol* 11:11. <https://doi.org/10.1038/nrneurol.2014.228>
- Cameron RB, Peterson YK, Beeson CC, Schnellmann RG (2017) Structural and pharmacological basis for the induction of mitochondrial biogenesis by formoterol but not clenbuterol. *Sci Rep* 7:10578. <https://doi.org/10.1038/s41598-017-11030-5>
- Casaletto JB, McClatchey AI (2012) Spatial regulation of receptor tyrosine kinases in development and cancer. *Nat Rev Cancer* 12:387-400. <https://doi.org/10.1038/nrc3277>
- Caunt CJ, Sale MJ, Smith PD, Cook SJ (2015) MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. *Nat Rev Cancer* 15:577-92. <https://doi.org/10.1038/nrc4000>
- Chang CR, Blackstone C (2007) Drp1 phosphorylation and mitochondrial regulation. *EMBO Rep* 8:1088-9; author reply 1089-90. <https://doi.org/10.1038/sj.embor.7401118>
- Choi YM, Kim HK, Shim W, Anwar MA, Kwon JW, Kwon HK, Kim HJ, Jeong H, Kim HM, Hwang D, Kim HS, Choi S (2015) Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation. *PLoS One* 10:e0135083. <https://doi.org/10.1371/journal.pone.0135083>
- Cohen P (2002) Protein kinases--the major drug targets of the twenty-first century? *Nat Rev Drug Discov* 1:309-15. <https://doi.org/10.1038/nrd773>
- Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell* 91:231-41. [https://doi.org/10.1016/s0092-8674\(00\)80405-5](https://doi.org/10.1016/s0092-8674(00)80405-5)
- De Rasmio D, Panelli D, Sardanelli AM, Papa S (2008) cAMP-dependent protein kinase regulates the mitochondrial import of the nuclear encoded NDUF54 subunit of complex I. *Cell Signal* 20:989-97. <https://doi.org/10.1016/j.cellsig.2008.01.017>
- Djeungoue-Petga MA, Lurette O, Jean S, Hamel-Cote G, Martin-Jimenez R, Bou M, Cannich A, Roy P, Hebert-Chatelain E (2019) Intramitochondrial Src kinase links mitochondrial dysfunctions and aggressiveness of breast cancer cells. *Cell Death Dis* 10:940. <https://doi.org/10.1038/s41419-019-2134-8>
- Dorsam RT, Gutkind JS (2007) G-protein-coupled receptors and cancer. *Nat Rev Cancer* 7:79-94. <https://doi.org/10.1038/nrc2069>
- Dossett LA, Kudchadkar RR, Zager JS (2015) BRAF and MEK inhibition in melanoma. *Expert Opin Drug Saf* 14:559-70. <https://doi.org/10.1517/14740338.2015.1011618>
- Drake JC et al (2021) Mitochondria-localized AMPK responds to local energetics and contributes to exercise and energetic stress-induced mitophagy. *Proc Natl Acad Sci U S A* 118:e2025932118. <https://doi.org/10.1073/pnas.2025932118>
- Fleischmann J, Feichtner A, DeFalco L, Kugler V, Schwaighofer S, Huber RG, Stefan E (2021) Allosteric kinase inhibitors reshape MEK1 kinase activity conformations in cells and in silico. *Biomolecules* 11:518. <https://doi.org/10.3390/biom11040518>
- Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. *J Clin Invest* 120:2355-69. <https://doi.org/10.1172/JCI40671>
- Gnaiger E (2020) Mitochondrial pathways and respiratory control. An introduction to OXPHOS analysis. 5th ed. *Bioenerg Commun* 2020.2. <https://doi.org/doi:10.26124/bec:2020-0002>



- Han H et al (2020) PINK1 phosphorylates Drp1<sup>S616</sup> to regulate mitophagy-independent mitochondrial dynamics. *EMBO Rep* 21:e48686. <https://doi.org/10.15252/embr.201948686>
- Hartmann JT, Haap M, Kopp HG, Lipp HP (2009) Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. *Curr Drug Metab* 10:470-81. <https://doi.org/10.2174/138920009788897975>
- Herzig S, Shaw RJ (2018) AMPK: guardian of metabolism and mitochondrial homeostasis. *Nat Rev Mol Cell Biol* 19:121-135. <https://doi.org/10.1038/nrm.2017.95>
- Javadov S, Jang S, Agostini B (2014) Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives. *Pharmacol Ther* 144:202-25. <https://doi.org/10.1016/j.pharmthera.2014.05.013>
- Jones R (2010) The roles of PINK1 and Parkin in Parkinson's disease. *PLoS Biol* 8:e1000299. <https://doi.org/10.1371/journal.pbio.1000299>
- Karaman MW et al (2008) A quantitative analysis of kinase inhibitor selectivity. *Nat Biotechnol* 26:127-32. <https://doi.org/10.1038/nbt1358>
- Karoulia Z, Gavathiotis E, Poulidakos PI (2017) New perspectives for targeting RAF kinase in human cancer. *Nat Rev Cancer* 17:676-691. <https://doi.org/10.1038/nrc.2017.79>
- Klaeger S et al (2017) The target landscape of clinical kinase drugs. *Science* 358:eaan4368. <https://doi.org/10.1126/science.aan4368>
- Kotrasova V, Keresztesova B, Ondrovicova G, Bauer JA, Havalova H, Pevala V, Kutejova E, Kunova N (2021) Mitochondrial kinases and the role of mitochondrial protein phosphorylation in health and disease. *Life (Basel)* 11:82. <https://doi.org/10.3390/life11020082>
- LaMoia TE et al (2022) Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis. *Proc Natl Acad Sci U S A* 119:e2122287119. <https://doi.org/10.1073/pnas.2122287119>
- Langeberg LK, Scott JD (2015) Signalling scaffolds and local organization of cellular behaviour. *Nat Rev Mol Cell Biol* 16:232-44. <https://doi.org/10.1038/nrm3966>
- Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. *Cell* 141:1117-34. <https://doi.org/10.1016/j.cell.2010.06.011>
- Lim S, Smith KR, Lim ST, Tian R, Lu J, Tan M (2016) Regulation of mitochondrial functions by protein phosphorylation and dephosphorylation. *Cell Biosci* 6:25. <https://doi.org/10.1186/s13578-016-0089-3>
- Lin A et al (2019) Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. *Sci Transl Med* 11:eaaw8412. <https://doi.org/10.1126/scitranslmed.aaw8412>
- Lucero M, Suarez AE, Chambers JW (2019) Phosphoregulation on mitochondria: integration of cell and organelle responses. *CNS Neurosci Ther* 25:837-58. <https://doi.org/10.1111/cns.13141>
- Martorana F, Motta G, Pavone G, Motta L, Stella S, Vitale SR, Manzella L, Vigneri P (2021) AKT inhibitors: new weapons in the fight against breast cancer? *Front Pharmacol* 12:662232. <https://doi.org/10.3389/fphar.2021.662232>
- Mayrhofer JE et al (2020) Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies. *Proc Natl Acad Sci U S A* 117:31105-31113. <https://doi.org/10.1073/pnas.2012150117>
- Morais VA et al (2014) PINK1 loss-of-function mutations affect mitochondrial complex I activity via Ndufa10 ubiquinone uncoupling. *Science* 344:203-7. <https://doi.org/10.1126/science.1249161>
- Nooren IM, Thornton JM (2003) Diversity of protein-protein interactions. *EMBO J* 22:3486-92. <https://doi.org/10.1093/emboj/cdg359>
- Parsons SJ, Parsons JT (2004) Src family kinases, key regulators of signal transduction. *Oncogene* 23:7906-9. <https://doi.org/10.1038/sj.onc.1208160>

- Prabu SK, Anandatheerthavarada HK, Raza H, Srinivasan S, Spear JF, Avadhani NG (2006) Protein kinase A-mediated phosphorylation modulates cytochrome c oxidase function and augments hypoxia and myocardial ischemia-related injury. *J Biol Chem* 281:2061-70. <https://doi.org/10.1074/jbc.M507741200>
- Ramms DJ, Raimondi F, Arang N, Herberg FW, Taylor SS, Gutkind JS (2021) G alpha s-protein kinase A (PKA) pathway signalopathies: the emerging genetic landscape and therapeutic potential of human diseases driven by aberrant G alpha s-PKA signaling. *Pharmacol Rev* 73:155-197. <https://doi.org/10.1124/pharmrev.120.000269>
- Rinaldi L, Delle Donne R, Borzacchiello D, Insabato L, Feliciello A (2018) The role of compartmentalized signaling pathways in the control of mitochondrial activities in cancer cells. *Biochim Biophys Acta Rev Cancer* 1869:293-302. <https://doi.org/10.1016/j.bbcan.2018.04.004>
- Röck R, Mayrhofer JE, Torres-Quesada O, Enzler F, Raffener A, Raffener P, Feichtner A, Huber RG, Koide S, Taylor SS, Troppmair J, Stefan E (2019) BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS. *Science Advances* 5:eaav8463. <https://doi.org/10.1126/sciadv.aav8463>
- Rodriguez-Hernandez MA et al (2020) Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer. *Redox Biol* 36:101510. <https://doi.org/10.1016/j.redox.2020.101510>
- Roskoski R Jr (2019) Properties of FDA-approved small molecule protein kinase inhibitors. *Pharmacol Res* 144:19-50. <https://doi.org/10.1016/j.phrs.2019.03.006>
- Shen HM, Liu ZG (2006) JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. *Free Radic Biol Med* 40:928-39. <https://doi.org/10.1016/j.freeradbiomed.2005.10.056>
- Taylor SS, Ilouz R, Zhang P, Kornev AP (2012a) Assembly of allosteric macromolecular switches: lessons from PKA. *Nat Rev Mol Cell Biol* 13:646-58. <https://doi.org/10.1038/nrm3432>
- Taylor SS, Keshwani MM, Steichen JM, Kornev AP (2012b) Evolution of the eukaryotic protein kinases as dynamic molecular switches. *Philos Trans R Soc Lond B Biol Sci* 367:2517-28. <https://doi.org/10.1098/rstb.2012.0054>
- Torres-Quesada O, Mayrhofer JE, Stefan E (2017) The many faces of compartmentalized PKA signalosomes. *Cell Signal* <https://doi.org/10.1016/j.cellsig.2017.05.012>
- Ubersax JA, Ferrell JE Jr. (2007) Mechanisms of specificity in protein phosphorylation. *Nat Rev Mol Cell Biol* 8:530-41. <https://doi.org/10.1038/nrm2203>
- Vuda M, Kamath A (2016) Drug induced mitochondrial dysfunction: Mechanisms and adverse clinical consequences. *Mitochondrion* 31:63-74. <https://doi.org/10.1016/j.mito.2016.10.005>
- Wallace DC (2012) Mitochondria and cancer. *Nat Rev Cancer* 12:685-98. <https://doi.org/10.1038/nrc3365>
- Wang N, Zhu P, Huang R, Wang C, Sun L, Lan B, He Y, Zhao H, Gao Y (2020) PINK1: The guard of mitochondria. *Life Sci* 259:118247. <https://doi.org/10.1016/j.lfs.2020.118247>
- Wang Y, An H, Liu T, Qin C, Sesaki H, Guo S, Radovick S, Hussain M, Maheshwari A, Wondisford FE, O'Rourke B, He L (2019) Metformin improves mitochondrial respiratory activity through activation of AMPK. *Cell reports* 29:1511-23.e5. <https://doi.org/10.1016/j.celrep.2019.09.070>
- Wynn ML, Ventura AC, Sepulchre JA, Garcia HJ, Merajver SD (2011) Kinase inhibitors can produce off-target effects and activate linked pathways by retroactivity. *BMC Syst Biol* 5:156. <https://doi.org/10.1186/1752-0509-5-156>
- Yang JY, Deng W, Chen Y, Fan W, Baldwin KM, Jope RS, Wallace DC, Wang PH (2013) Impaired translocation and activation of mitochondrial Akt1 mitigated mitochondrial oxidative phosphorylation Complex V activity in diabetic myocardium. *J Mol Cell Cardiol* 59:167-75. <https://doi.org/10.1016/j.yjmcc.2013.02.016>

- Yu C, Minemoto Y, Zhang J, Liu J, Tang F, Bui TN, Xiang J, Lin A (2004) JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. *Mol Cell* 13:329-40. [https://doi.org/10.1016/s1097-2765\(04\)00028-0](https://doi.org/10.1016/s1097-2765(04)00028-0)
- Zhang CS, Lin SC (2016) AMPK Promotes Autophagy by Facilitating Mitochondrial Fission. *Cell Metab* 23:399-401. <https://doi.org/10.1016/j.cmet.2016.02.017>
- Zhang H, Liu B, Li T, Zhu Y, Luo G, Jiang Y, Tang F, Jian Z, Xiao Y (2018) AMPK activation serves a critical role in mitochondria quality control via modulating mitophagy in the heart under chronic hypoxia. *Int J Mol Med* 41:69-76. <https://doi.org/10.3892/ijmm.2017.3213>
- Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. *Nat Rev Cancer* 9:28-39. <https://doi.org/10.1038/nrc2559>
- Zhang R, Loughran TP Jr. (2011) Off-target effects of tyrosine kinase inhibitors: Beauty or the Beast? *Leuk Lymphoma* 52:556-7. <https://doi.org/10.3109/10428194.2011.560694>
- Zheng L, Wang C, Luo T, Lu B, Ma H, Zhou Z, Zhu D, Chi G, Ge P, Luo Y (2017) JNK activation contributes to oxidative stress-induced parthanatos in glioma cells via increase of intracellular ROS production. *Mol Neurobiol* 54:3492-3505. <https://doi.org/10.1007/s12035-016-9926-y>

**Copyright:** © 2022 The authors. This is an Open Access preprint (not peer-reviewed) distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are credited. © remains with the authors, who have granted MitoFit Preprints an Open Access publication license in perpetuity.

